Where your ideas
become new therapies
Working alongside academic researchers, biotech and pharma, we have built a strong track record of discovering new potential medicines and therapies.
Expertise in drug discovery
We combine deep pre-clinical drug discovery expertise with state-of-the-art capabilities to drive innovation.
Investing with impact
We provide capital for early-stage drug discovery programmes and invest in spin-offs and innovative biotech companies.
Outlicensing
We outlicense de-risked preclinical assets to pharma and biotech partners, enabling their continued development while enhancing value for the original innovators.
A pipeline built on partnerships
120
+
drug discovery projects initiated
10
+
different countries
20
+
partnerships with pharma or biotech
100
+
million euros invested
Our pipeline is your opportunity. Let’s turn science into impact.
Research-driven partnerships
We partner with academic researchers, Tech Transfer Offices and biotech innovators to advance promising science beyond early discovery. By combining world-class drug discovery expertise with dedicated investment, we advance innovative concepts towards preclinical therapeutic candidates.
Our core principles include:
- Collaborative advancement of early-stage discovery projects
- Value creation through a shared-risk, shared-reward model
- Access to state-of-the art drug development expertise and infrastructure
Outlicensing and investments
CD3 advances early-stage academic discoveries into preclinical drug candidates, with the potential for further clinical development. Once a programme reaches sufficient maturity, we deliver further value through licensing to pharmaceutical partners.
CD3 also provides capital to support the creation of new ventures or invest in early-stage biotech companies with promising therapeutic programmes. CD3 remains actively involved in the ventures and companies it invests in, supporting them through key stages of development.
Success stories
Pioneering TRPM3 Inhibitors for Non‑Opioid Pain Relief
Pioneering TRPM3 Inhibitors for Non‑Opioid Pain Relief
Read More
From Hippo mutant flies to YAP/TEAD inhibitors for hard-to-treat cancers
From Hippo mutant flies to YAP/TEAD inhibitors for hard-to-treat cancers
Read More
From Academic Insight to Phase II: Birth of a First in Class Dengue Antiviral Programme
From Academic Insight to Phase II: Birth of a First in Class Dengue Antiviral Programme
Read More News
CD3 announces investment in Enedra Therapeutics to advance drug discovery programmes from its proprietary CASPAROV platform for difficult to treat cancers
CD3 announces investment in Enedra Therapeutics to advance drug discovery programmes from its proprietary CASPAROV platform for difficult to treat cancers
Read More
Promising antiviral drug candidate against dengue gets new opportunity for further development
Promising antiviral drug candidate against dengue gets new opportunity for further development
Read More
KU Leuven joins EndLyz Therapeutics’ fight against Parkinson’s disease
KU Leuven joins EndLyz Therapeutics’ fight against Parkinson’s disease
Read More